White-Koning M - Search Results

1

Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.

White-Koning M, Civade E, Geoerger B, Thomas F, Le Deley MC, Hennebelle I, Delord JP, Chatelut E, Vassal G. White-Koning M, et al. Clin Cancer Res. 2011 Jul 15;17(14):4862-71. doi: 10.1158/1078-0432.CCR-10-3278. Epub 2011 Jun 8. Clin Cancer Res. 2011. PMID: 21653689 Clinical Trial.

2

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP. Thomas F, et al. Eur J Cancer. 2009 Sep;45(13):2316-23. doi: 10.1016/j.ejca.2009.05.007. Epub 2009 Jun 10. Eur J Cancer. 2009. PMID: 19523815

3

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Chatelut E, et al. Br J Cancer. 2012 Sep 25;107(7):1100-6. doi: 10.1038/bjc.2012.357. Epub 2012 Aug 28. Br J Cancer. 2012. PMID: 22929884 Free PMC article.

4

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J. Puisset F, et al. Br J Clin Pharmacol. 2013 Nov;76(5):734-40. doi: 10.1111/bcp.12098. Br J Clin Pharmacol. 2013. PMID: 23432476 Free PMC article. Clinical Trial.

5

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.

Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M. Chalret du Rieu Q, et al. Invest New Drugs. 2014 Oct;32(5):985-94. doi: 10.1007/s10637-014-0118-1. Epub 2014 May 31. Invest New Drugs. 2014. PMID: 24875134 Clinical Trial.

6

Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.

Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, Chatelut E, Ferron G. Chalret du Rieu Q, et al. Cancer Chemother Pharmacol. 2014 Sep;74(3):571-82. doi: 10.1007/s00280-014-2525-6. Epub 2014 Jul 23. Cancer Chemother Pharmacol. 2014. PMID: 25053386 Clinical Trial.

7

Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.

Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, Thomas F. Imbs DC, et al. Invest New Drugs. 2016 Feb;34(1):41-8. doi: 10.1007/s10637-015-0304-9. Epub 2015 Nov 16. Invest New Drugs. 2016. PMID: 26572909 Clinical Trial.

8

Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, Chatelut E, Thomas F. Sauzay C, et al. Pharmacol Res. 2016 Aug;110:89-95. doi: 10.1016/j.phrs.2016.05.012. Epub 2016 May 10. Pharmacol Res. 2016. PMID: 27178732

9

Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1. Pharmacol Res. 2016. PMID: 27378568

10

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ. White-Koning M, et al. Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12. Eur J Cancer. 2018. PMID: 29335155 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38 results

Search Page